Core Insights - The report highlights the significant role of CFOs in listed companies, with the total compensation for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] CFO Demographics - The age distribution of CFOs shows that those aged 40-50 constitute 54% of the market, while CFOs over 50 account for 35%, and those under 40 make up 11% [1] - In terms of educational background, 71% of CFOs hold a bachelor's degree, 23% have a master's degree, and only 3% possess a doctoral degree, with only one CFO, Yan Hongyu from Yangpu Medical, holding a PhD [1] Compensation Analysis - The average annual salary for CFOs in A-share medical device companies is 1.0652 million yuan [1] - The distribution of salaries shows that 31% earn below 500,000 yuan, 43% earn between 500,000 and 1 million yuan, 20% earn between 1 million and 2 million yuan, and 6% earn above 2 million yuan [1] - The top three highest-paid CFOs are Zhao Yun from Mindray Medical at 8.4134 million yuan, Liu Lihua from Yuyue Medical at 4.3136 million yuan, and Jing Xiaokuan from Wandong Medical at 1.6412 million yuan [1] Salary Changes - Among CFOs with over two years of tenure, Zhang Qiu from Kangtong Medical experienced the largest salary decrease of 31.23% year-on-year, while Xu Ning from Mcland saw the highest salary increase of 165.59% year-on-year [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - In the medical device sector, the average annual salary of CFOs is 1.0652 million yuan, with 31% earning below 500,000 yuan, 43% between 500,000 and 1 million yuan, 20% between 1 million and 2 million yuan, and 6% above 2 million yuan [2] - The age distribution of CFOs shows that 54% are aged between 40 and 50, 35% are over 50, and 11% are 40 or younger, with the youngest being 30 years old and the oldest being 65 years old [1] Group 2 - The top three highest-paid CFOs in the medical device sector are Zhao Yun from Mindray Medical with 8.4134 million yuan, Liu Lihua from Yuyue Medical with 4.3136 million yuan, and Jing Xiaoqian from Wandong Medical with 1.6412 million yuan [2] - The CFO with the largest salary decrease in 2024 is Zhang Qiu from Kangtong Medical, with a year-on-year decrease of 31.23%, while Xu Ning from Mcland saw the largest increase at 165.59% [2] - The educational background of CFOs shows that 71% hold a bachelor's degree, 23% a master's degree, and only 3% hold a doctoral degree, with only one CFO having a PhD [1]

从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为3%、71%、23%、3%。其 中，获得博士学历的CFO仅一人，为阳普医疗的闫红玉。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 从薪酬分布看，A股医疗设备公司CFO年薪平均值为106.52万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各区间的人数占比分别为31%、43%、20%、6%。 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有35家上市医疗设备公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到54%；50岁以上的CFO占比 为35%；40岁及以下CFO群体占比为11%。其中，目前仍任职的最年轻的上市公司CFO年龄30岁，为博 迅 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有35家上市医疗设备公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到54%；50岁以上的CFO占比 为35%；40岁及以下CFO群体占比为11%。其中，目前仍任职的最年轻的上市公司CFO年龄30岁，为博 迅生物的金曼；最年长上市公司CFO年龄65岁，为超研股份的陈小波。 从薪酬分布看，A股医疗设备公司CFO年薪平均值为106.52万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各区间的人数占比分别为31%、43%、20%、6%。 其中，年薪排行前三的CFO分别为迈瑞医疗的赵云、鱼跃医疗的刘丽华、万东医疗的井晓权，三人年 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为3%、71%、23%、3%。其 中，获得博士学历的CFO仅一人，为阳普医疗的闫红玉。 从薪酬分布看，A股医疗设备公司CFO年薪平均值为106.52万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各区间的人数占比分别为31%、43%、20%、6%。 其中，年薪排行前三的CFO分别为迈瑞医疗的赵云、鱼跃医疗的刘丽华、万东医疗的井晓权，三人年薪 分别为841.34万元、431.36万元、164.12万元。 从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），2024年港通医疗的张秋薪酬降幅最大，同比 降幅达31.23%；麦澜德的徐宁薪酬增幅最大，同比涨幅达165.59%。 分行业来看，统计数据显示，剔除20 ...

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - In the medical device sector, the average annual salary of CFOs is 1.0652 million yuan, with 31% earning below 500,000 yuan, 43% between 500,000 and 1 million yuan, 20% between 1 million and 2 million yuan, and 6% earning above 2 million yuan [2] - The top three highest-paid CFOs in the medical device industry are Zhao Yun from Mindray Medical with 8.4134 million yuan, Liu Lihua from Yuyue Medical with 4.3136 million yuan, and Jing Xiaoqian from Wandong Medical with 1.6412 million yuan [2] Group 2 - The age distribution of CFOs shows that those aged 40-50 make up 54%, while 35% are over 50, and 11% are 40 or younger [1] - The educational background of CFOs indicates that 71% hold a bachelor's degree, 23% a master's degree, and only 3% have a doctoral degree, with only one CFO holding a PhD [1] - The largest salary decrease among CFOs in 2024 was observed in Zhang Qiu from Kangtong Medical, with a year-on-year decline of 31.23%, while Xu Ning from Mcland saw the largest increase at 165.59% [2]

Company Overview - WanDong Medical's stock price closed at 17.47 yuan on July 31, 2025, down 1.30% from the previous trading day [1] - The trading volume for the day was 64,875 hands, with a transaction amount of 115 million yuan [1] - The company specializes in the research, production, and sales of medical devices, including medical X-ray equipment and magnetic resonance imaging systems [1] Financial Metrics - As of July 31, 2025, WanDong Medical's current price-to-earnings (P/E) ratio is 87.60 times, and the price-to-book (P/B) ratio is 2.61 times [1] - On the same day, the net inflow of main funds into WanDong Medical was 202.21 thousand yuan [1]

Core Viewpoint - The DSA (Digital Subtraction Angiography) market in China is experiencing significant growth, driven by increasing demand for vascular imaging and intervention, with a competitive landscape featuring both foreign and domestic brands [1][9][20]. Group 1: Overview of DSA Technology - DSA machines utilize X-rays and contrast agents to visualize blood vessels, aiding in the diagnosis of various vascular diseases [2][4]. - The DSA system comprises several components, including X-ray generation, digital imaging, mechanical systems, control systems, and image processing systems [3]. Group 2: Clinical Applications - DSA is crucial for diagnosing cardiovascular diseases, brain vascular diseases, and peripheral vascular diseases, as well as for performing interventional treatments [4][6]. - It serves as the gold standard for coronary artery disease diagnosis and is essential for assessing conditions like aneurysms and vascular blockages [4][6]. Group 3: Market Size and Dynamics - In 2024, the DSA equipment bidding market in China involved 829 procurement units, with a total bid amount of approximately 8.853 billion yuan, averaging 7.484 million yuan per unit [9][11]. - The first half of 2025 saw 411 units bid, totaling around 3.168 billion yuan [9]. Group 4: Competitive Landscape - The DSA market is dominated by foreign brands such as GE Healthcare, Philips, and Siemens, which hold over 90% market share in terms of revenue [13][15]. - Domestic brands like Neusoft and United Imaging are increasingly competitive in the mid-to-low-end market and are making strides into the high-end segment [13][15]. Group 5: Regional Insights - Key regions for DSA equipment procurement include Guangdong, Zhejiang, and Sichuan, which collectively account for 28% of the total bid amount [11]. Group 6: Future Trends - The DSA market is expected to expand further due to an aging population and rising incidence of cardiovascular diseases, alongside government initiatives promoting equipment upgrades [20][22]. - Domestic brands are anticipated to gain more market share, potentially altering the current dominance of foreign brands [20][22].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 产品种类：银行理财 ● 本次现金管理总额：募集资金1亿元、自有资金1亿元 ● 履行的审议程序：2025年3月20日召开的第十届董事会第六次会议、第十届监事会第六次会议及2025 年4月16日召开的2024年年度股东大会审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金 管理的议案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提高募集资金和自有资金效率，合理利 用部分闲置募集资金及自有资金，在确保不影响募集资金项目建设和使用、募集资金和自有资金安全的 情况下，增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金1亿元,自有资金1亿元。 （三）资金来源及相关情况 ■ 2025年7月2日，公司以3,000万元募集资金购买了中国建设银行北京市分行单位人民币定制型结构性存 款，本产品本金纳入中国建设银行内部资金 ...

北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 1 亿元、自有资金 1 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 证券代码：600055 证券简称：万东医疗 编号：临 2025-034 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金 1 亿元,自有资金 1 亿元。 （三）资金来源及相关 ...